Trevi Therapeutics, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Trevi Therapeutics, Inc.Headquarters: New Haven, 
                        CT, United States
                    
Employees: 26
CEO: Ms. Jennifer L. Good

                                    NASDAQ: TRVI
                                
                                            +2.47%
                                            
Market Cap$356.6 Million

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

Trevi Therapeutics, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Trevi Therapeutics, Inc. market capitalization over time

Evolution of Trevi Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Trevi Therapeutics, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Tweets by Trevi Therapeutics, Inc.

Financials

Last Financial Reports Date	Dec. 31, 2023
Revenue TTM	$0
EBITDA	$-33,800,000
Gross Profit TTM	$0
Profit Margin	0.00%
Operating Margin	0.00%
Quarterly Revenue Growth	%